Nuvation Bio Inc. (NUVB)
NYSE NYSE Primary 
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Nuvation Bio Inc. (NUVB) could be a good stock pick from a technical perspective. NUVB recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript
Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Kaveri Pohlman - Clear Street Soumit Roy - Jones Research Michael Yee - Jefferies Yaron Werber - TD Cowen Operator Good afternoon and welcome to the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call.
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.
Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes
Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of cash runway and additional liquidity options to support taletrectinib's launch and ongoing research. Despite strong data, competition from Bristol Myers Squibb's repotrectinib and other ROS1 players, and market hesitancy pose challenges for taletrectinib's market penetration.
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism.
